CoCites: A citation-based method for searching scientific literature

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan, Paula J Spitzler, Jonathon P Orme, M Raymond V Finlay, Richard A Ward, Martine J Mellor, Gareth Hughes, Amar Rahi, Vivien N Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H P Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R Ranson, William Pao. Cancer Discov 2014
Times Cited: 1324

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You. Lancet Oncol 2011
Times Cited: 3086

List of shared articles

Times cited

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo .
Mengzhen Lai, Tao Zhang, Hao Chen, Peiran Song, Linjiang Tong, Jiaying Chen, Yingqiang Liu, Yi Ning, Fang Feng, Yan Li,[...]. J Cancer 2023

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.
Matteo Canale, Kalliopi Andrikou, Ilaria Priano, Paola Cravero, Luigi Pasini, Milena Urbini, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte, Paola Ulivi. Cancers (Basel) 2022

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu. Thorac Cancer 2022

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.
Meredith S Eno, Jason D Brubaker, John E Campbell, Chris De Savi, Timothy J Guzi, Brett D Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim,[...]. J Med Chem 2022

Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.
Sofia Lampaki, Giannis Mountzios, Vassilis Georgoulias, Aggeliki Rapti, Ioannis Xanthakis, Sofia Baka, Dimitrios Mavroudis, Epaminondas Samantas, Elias Athanasiadis, Flora Zagouri,[...]. Future Oncol 2022

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
Hyun Ae Jung, Min Hee Hong, Hyun Woo Lee, Kyung Hee Lee, Il Hwan Kim, Young Joo Min, Hee Kyung Ahn, Byoung Yong Shim, Yoon Hee Choi, Yun-Gyoo Lee,[...]. Transl Lung Cancer Res 2022

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.
Yue Zeng, Danlei Yu, Wentao Tian, Fang Wu. Curr Opin Oncol 2022

An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer.
Jingyi Wang, Lin Wu. Expert Opin Pharmacother 2022

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
Hidetoshi Hayashi, Kimio Yonesaka, Atsushi Nakamura, Daichi Fujimoto, Koichi Azuma, Shinya Sakata, Motoko Tachihara, Satoshi Ikeda, Toshihide Yokoyama, Osamu Hataji,[...]. Lung Cancer 2022